Compass cuts 30% of staff as late-stage psilocybin drug trials face new delays
The company now expects top-line data from its main Phase 3 trial in the second quarter of 2025.
The post Compass cuts 30% of staff as late-stage psilocybin drug trials face new delays appeared first on Green Market Report.
